现实情况是,面对平时缺乏沟通、每次开会前才把一大堆材料提交独董审阅的上市公司,大部分独董只能走走形式、签签字,否则,结局很可能跟天目药业独董郑立新和徐壮城一样,被上市公司以“未核实情况就在董事会会议上投反对票,给公司造成负面影响,直接损害了广大投资者的利益,不符合继续担任天目药业独立董事的资格”为由罢免 The reality is that in the face of the usual lack of communication, only a large amount of materials are submitted to listed companies that are reviewed by independent directors before each meeting. Most of the independent directors can only walk away and sign the signature. Otherwise, the outcome may well be the same with that of Tianmu Pharmaceutical Dong Zhenglixin and Xu Zhuangcheng, listed companies to “not verified the situation in the board meeting to vote against, causing negative impact on the company, directly to the detriment of the interests of investors, does not meet the continued as Tianmu independent director of medicine Qualifications ”as the basis for the recall